Introduction – The objective of this study was to update the epidemiology of heart failure (HF) in France in 2022. Methods – Adults hospitalized for HF in 2022 were identified in the National Health Data System (SNDS) based on hospital diagnoses coded in the Medical Information Systems Program, Surgery and Obstetrics Section (PMSI-MCO), and followed for one year. The first hospital stay of the year was retained as the index hospitalization. The prevalence of HF was estimated by combining hospitalization data with 100% coverage for long-term conditions associated with HF. Patients and their hospital stays were described based on sociodemographic and medical information available in the SNDS. Rates in the French population were calculated using population estimates produced by the National Institute of Statistics and Economic Studies (INSEE). Results – In 2022, 181,178 adults were hospitalized for HF in France, representing a crude rate of 339.3 per 100,000 inhabitants, and 1,376,692 prevalent cases of HF were recorded, representing an estimated prevalence of 2.6% in the adult population. The average age at the time of hospitalization was higher among women (83.3 years) than among men (77.7 years), while rates were lower among women than among men (318.0 per 100,000 vs. 362.7 per 100,000). The hospitalization rate was 1.6 times higher among people living in the most socioeconomically disadvantaged municipalities compared to those living in the least disadvantaged municipalities. The departments of Hauts-de-France, Réunion, and certain departments in Normandy and the Grand Est region had much higher rates than other departments. The average length of hospitalization for HF was 10.6 days. In total, 17.6% of patients were admitted to a cardiac intensive care unit (CICU) and 4.0% to the intensive care unit (ICU). The case-fatality rate was 10.2% in-hospital, 12.4% at 30 days, 26.5% at 6 months, and 34.0% at 1 year. Only 20.1% were admitted to medical and rehabilitation care (MRC) within 6 months, and 47.9% of patients alive at 1 year were receiving a combination of ACE inhibitors/ARBs and beta-blockers. Conclusion – The high number of people hospitalized for HF, the variation in the corresponding rate across departments, and the socioeconomic context necessitate more ambitious general cardiovascular prevention, particularly in certain regions, and a significant adaptation of healthcare services (primary care, SMR, etc.). The short-term outcomes for patients could be improved by optimizing care through better adherence to guidelines and closer follow-up that takes into account patients’ social circumstances.